View |
|
BR-948
|
Insulin Human (rDNA)
|
Humulin N Kwikpen
|
100 IU/mL
|
Suspension For Injection (S.C.)
|
Antidiabetics
|
Lilly France(Fegersheim)
|
France
|
Renewal
|
19 January 2024
|
27 May 2029
|
View |
|
BR-950
|
Insulin Human (rDNA)
|
Humulin 70/30 Kwikpen
|
100 IU/mL
|
Suspension For Injection (S.C.)
|
Antidiabetics
|
Lilly France(Fegersheim)
|
France
|
Renewal
|
24 January 2024
|
27 May 2029
|
View |
|
BR-952
|
Trastuzumab Emtansine
|
Kadcyla
|
160 mg
|
Powder For Conc. For Sol'N For Iv Infusion
|
Monoclonal Antibody
|
F. Hoffmann-La Roche AG
|
Switzerland
|
Renewal
|
10 May 2024
|
30 June 2029
|
View |
|
BR-953
|
Trastuzumab Emtansine
|
Kadcyla
|
100 mg
|
Powder For Concentrate For Solution For I.V. Infusion
|
Monoclonal Antibody
|
F. Hoffmann-La Roche AG
|
Switzerland
|
Renewal
|
06 May 2024
|
30 June 2029
|
View |
|
BR-955
|
Varicella Virus Vaccine, Live
|
Varivax
|
1350 PFU/0.5 mL
|
Lyophilized Powder For Solution
for Injection (SC)
|
Vaccine
|
Merck Sharp & Dohme Corp.
|
United States of America
|
Renewal
|
28 June 2024
|
14 July 2029
|
View |
|
BR-957
|
Insulin Lispro (rDNA)
|
Humalog Mix25 Kwikpen
|
100 Units/mL (3.5 mg/mL) Suspension for Injection (SC) (25% Insulin Lispro Solution + 75% Insulin Lispro Protamine Suspension)
|
Suspension for Injection (SC)
|
-
|
Eli Lilly Italia S.p.A.
|
Italy
|
Initial (Variation)
|
25 October 2022
|
25 October 2027
|
View |
|
BR-959
|
Clostridium botulinum Type A Toxin
|
Dysport
|
300 IU
|
Freeze-Dried Powder for Solution for Injection
(IM/SC)
|
-
|
IPSEN Biopharm Limited.
|
United Kingdom
|
Initial (Variation)
|
22 November 2023
|
22 November 2028
|
View |
|
BR-961
|
Pegfilgrastim
|
Pegstim
|
6mg/ 0.6 mL
|
Solution for Injection (SC)
|
Colony Stimulating Factors
|
Cadila Healthcare Ltd.
|
India
|
Renewal
|
05 May 2024
|
18 August 2029
|
View |
|
BR-962
|
Humulin N
|
Insulin Human (rDNA)
|
100 IU/mL
|
Suspension For Injection (SC)
|
-
|
Eli Lily and Company
|
USA
|
-
|
18 May 2021
|
20 April 2026
|
View |
|
BR-968
|
Bevacizumab
|
Avastin
|
100mg/ 4mL (25 mg/mL)
|
Concentrate for Solution for IV Infusion
|
Monoclonal Antibody
|
F. Hoffman-La Roche Ltd.
|
Switzerland
|
Renewal
|
12 June 2024
|
26 August 2029
|
View |
|
BR-969
|
Bevacizumab
|
Avastin
|
400 mg/16 mL (25mg/mL)
|
Concentrate for Solution for
Infusion (IV)
|
-
|
F. Hoffmann-La Roche, Ltd.
|
|
Initial (Variation)
|
24 March 2023
|
24 March 2028
|
View |
|
BR-971
|
Epoetin Alfa (Recombinant Human Erythropoietin)
|
Espogen
|
2,000 I.U./0.5 mL
|
Solution for Injection (S.C./I.V.)
|
Hematopoietic Growth Factor
|
LG Chem, Ltd.
|
Korea
|
Initial (Variation) [Correction]
|
15 March 2023
|
09 February 2028
|
View |
|
BR-972
|
Recombinant Human Erythropoietin
|
Espogen
|
4000 IU/ 0.4 mL
|
Solution For Injection
|
Hematopoietic Growth Factor
|
LG Life Sciences Ltd.
|
Korea
|
Automatic Renewal
|
21 September 2021
|
12 September 2026
|
View |
|
BR-975
|
Human Chorionic Gonadotropin
|
PUBERGEN
|
5000 IU
|
Lyophilized Powder for Solution for Injection (IM)
|
Gonadotrophic Hormone
|
Sanzyme (P) Limited
|
India
|
Renewal
|
13 April 2022
|
11 April 2027
|
View |
|
BR-977
|
Recombinant Human Insulin (70% Isophane/30% Soluble)
|
Humulin 70/30
|
100 IU/mL
|
Suspension for Injection (SC)
|
Intermediate-acting Insulin
|
Eli Lilly & Company
|
U.S.A.
|
Automatic Renewal
|
17 March 2023
|
21 July 2028
|
View |
|
BR-980
|
Insulin Human (rDNA)
|
Humulin R
|
100 IU/mL
|
Suspension for Injection (SC)
|
-
|
Eli Lilly and Company
|
U.S.A.
|
-
|
18 January 2022
|
22 May 2026
|
View |
|
BR-981
|
Epoetin Alfa
|
Renogen
|
10,000 IU/mL
|
Solution for Injection (IV/SC)
|
Antianemic Preparations
|
Intas Pharmaceuticals, Ltd.
|
India
|
Renewal
|
24 May 2024
|
03 October 2029
|
View |
BR-983_PI_01.pdf
|
BR-983
|
Ustekinumab
|
Stelara
|
90 mg/mL
|
Solution for Injection (SC)
|
Interleukin Inhibitors :
|
Cilag AG
|
Switzerland
|
Initial
|
09 February 2022
|
14 October 2024
|
View |
|
BR-986
|
Menotrophin
|
Gynogen HP
|
75 IU
|
Lyophilized Powder for Solution for Injection
(IM/SC)
|
Gonadotropins
|
Sanzyme (P) Ltd.
|
India
|
Initial (from Monitored Release)
|
27 July 2022
|
11 April 2027
|
View |
BR-987_PI_01.pdf
|
BR-987
|
Omalizumab
|
Xolair
|
150 mg (150 mg in 1.2 mL)
|
Lyophilized Powder for Injection (SC)
|
-
|
Novartis Pharma Stein AG
|
Switzerland
|
Renewal
|
05 August 2021
|
24 January 2026
|